Recombinant human activated protein C in sepsis: Assessing its clinical use

American Journal of the Medical Sciences

Volumn 328, Issue 4, 2004, Pages 215-219

  Haley, Michael ^a,b   Cui, Xizhong ^a   Minneci, Peter C ^a   Deans, Katherine J ^a   Natanson, Charles ^a   Eichacker, Peter Q ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Activated protein C; Cost effectiveness; Mortality; Sepsis; Therapy

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN III; DROTRECOGIN; HEPARIN; STEROID; TISSUE FACTOR PATHWAY INHIBITOR;

BLEEDING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG MECHANISM; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; META ANALYSIS; MORTALITY; PHASE 3 CLINICAL TRIAL; REVIEW; SEPSIS; SYSTEMATIC REVIEW;

EID: 2542586508     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200410000-00004     Document Type: Article

References (25)

1. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
2. Matthay M. Severe sepsis: a new treatment with both anticoagulant and anti-inflammatory properties. N Engl J Med 2001;344:759-62.
3. Okie S. New treatment found to cut sepsis deaths. The Washington Post. Feb. 10, 2001. p A2.
4. Anonymous. FDA Briefing document: anti-infective committee drotrecogin alfa (activated) [recombinant human activated protein C (rhAPC)]. Available at: http://www.fda.gov/ ohrms/dockets/ac01/briefing/379b1_02_FDAbriefing.doc 1 A.D.
5. Warren S, Suffredini A, Eichacker PQ, et al. Risks and benefits of activated protein c treatment for severe sepsis. N Engl J Med 2002;347:1027-30.
6. Eichacker PQ, Natanson C. (Sounding Board). Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials. Crit Care Med 2003;31:S94-6.
7. FDA News-Press Release. Department of Health and Human Services. November 21, 2001. Available at: www.fda.gov/bbs/ topics/NEWS/2001/NEW00780.html.
8. Eichacker PQ, Parent C, Kalil A, et al. Risk and efficacy of anti-inflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002;166:1197-205.
9. Angus DC, Linde-Zwirble WT, Clermont G, et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003;31:1-11.
10. Banks SM, Gerstenberger E, Eichacker PQ, et al. Long-term cost effectiveness of drotecogin alfa (activated): an unanswered question. Crit Care Med 2003;31:308-9.
11. Rose JC, Unis AS. A mortality index for postmarketing surveillance of new medications. Am J Emerg Med 2000;18: 176-9.
12. Edwards IR. Safety monitoring of new anti-malarials in immediate post-marketing phase. Med Trop (Mars) 1998;58: 93-6.
13. Westerholm B. The rationale for a post-marketing surveillance. Hum Reprod 1987;2:41-4.
14. Tanzi M. Use of drotrecogin alfa (activated) (Xigris™) for the treatment of severe sepsis. Medical Use Evaluation by Novation®, The Supply Company of VHA & UHC. April 2003.
15. Warren BL, Eid A, Singer P et al., for the KyberSept Trial Study Group. High-dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA 2001;286:1869-78.
16. Abraham E, Reinhart K, Svoboda P. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. JAMA 2003; 290:238-47.
17. Davidson BL, Geert WH, Lensing AW. Low-dose heparin for severe sepsis. N Engl J Med 2002;347:1036-7.
18. Goldhaber SZ. PREVENT (PRospective EValuation of Dalteparin Efficacy in Immobilized PantieNts Trial) trial. Presented at the 32nd Critical Care Congress. San Antonio, Texas, February, 2003.
19. Chadda K, Annane D. The use of corticosteroids in severe sepsis and acute respiratory distress syndrome. Ann Med 2003;34:582-9.
20. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-71.
21. Bollaert PE, Charpentier C, Levy B, et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998;26:645-50.
22. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999;27:723-32.
23. Chawla K, Kupfer Y, Goldman I. Hydrocortisone reverses refractory septic shock. Crit Care Med 1999;27:A33.
24. Yildiz O, Doganay M, Aygen B, et al. Physiological-dose steroid therapy in sepsis [ISRCTN36253388]. Crit Care 2002; 6:251-9.
25. Minneci PC, Deans KJ, Banks SM, et al. Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 2004;141:47-56.